247 - It’s a Small World After All: Prevention and Treatment in the Expanding World of Pediatric Immunocompromised Hosts

Wednesday, October 22, 2025

1:45 PM - 3:00 PM US ET

Location: B302-B304

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Kengo Inagaki, MD

Professor
University of Michigan / C.S. Mott Children's Hospital
Novi, MI, United States
Natalie Dailey Garnes, MD, MPH, MS (she/her/hers)

Associate Professor
The University of Texas MD Anderson Cancer Center

Faculty(s)

Juan Pablo Torres, MD, PhD

Vice Dean
Department of Pediatrics, University of Chile
Santiago, Region Metropolitana, Chile
Lara Danziger-Isakov, MD, MPH

Professor
Infectious Disease
Cincinnati Children's Hospital
Cincinnati, OH, United States
WO

William Otto, MD, MSCE (he/him/his)

Assistant Professor
Cincinnati Children's Hospital Medical Center
Cincinnati, OH, United States

Disclosure(s):

Kengo Inagaki, MD: AstraZeneka: Grant/Research Support; Elsevier: Honoraria, honoraria for book chapter writing

Natalie J. Dailey Garnes, MD, MPH, MS: No financial relationships to disclose.

Juan Pablo Torres, MD, PhD: MSD LATAM: Honoraria; Pfizer, Inc.: Honoraria; Sanofi Pasteur LLC: Honoraria

Lara A. Danziger-Isakov, MD, MPH: AiCuris.: Grant/Research Support; Ansun BioPharma: Grant/Research Support; Astellas Pharma Global Development, Inc: Advisor/Consultant, Grant/Research Support; kamada: Advisor/Consultant; Merck Sharp & Dohme Corporation: Grant/Research Support; Pfizer (Any division): Grant/Research Support; Takeda Pharmaceuticals: Grant/Research Support

William R. Otto, MD, MSCE: No financial relationships to disclose.

Learning Objectives:

At the conclusion of this session, participants will be able to:

discuss current approaches to infection prophylaxis in neutropenic hosts and their limitations and solutions;
describe how antimicrobial use can be optimized in pediatric patients with fever and neutropenia;
describe the evidence-based use of letermovir in pediatric transplant recipients.

Presentations:

1:45 PM - 2:10 PM US ET

Personalized Antibiotic Prophylaxis Plans in Response to Antibiotic-Resistant Organisms
Speaker: William R. Otto, MD, MSCE (he/him/his) – Cincinnati Children's Hospital Medical Center
2:10 PM - 2:35 PM US ET

Treat Them Just Right – Antimicrobial Stewardship in Fever and Neutropenia
Speaker: Juan Pablo Torres, MD, PhD – Department of Pediatrics, University of Chile
2:35 PM - 3:00 PM US ET

Letermovir Prophylaxis for CMV Infection in Pediatric Transplant Recipients: 2025 Updates
Speaker: Lara A. Danziger-Isakov, MD, MPH – Cincinnati Children's Hospital